A Phase 2, Open-Label, Multicenter Study to Explore the Efficacy and Safety of Mongersen in Subjects with Active Ulcerative Colitis

Grants and Contracts Details

StatusFinished
Effective start/end date2/1/16 → 1/31/18

Funding

  • Celgene: $7,650.00